President Joe Biden is undermining one of his key—and deeply personal—health policy goals by trying to lower drug prices, the pharmaceutical lobby is warning the White House.
Efforts to empower the government to negotiate with drugmakers for better prices on medicines will stifle innovation and restrict patient access to cancer treatments, the Pharmaceutical Research and Manufacturers of America wrote in a letter sent Tuesday to the White House.
The letter details concerns over the Biden administration’s reconsideration of “march-in authority,” which allows the government to license an invention to a third party if a patent holder fails to make it ...